BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Begins Commercializing XGEVA® (Denosumab) in China
June 30, 2020 19:30 ET | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
January 02, 2020 08:15 ET | BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
October 31, 2019 16:00 ET | BeiGene, LTD.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China  • Companies to Jointly Develop 20 Amgen Oncology Pipeline...